# Bioventus plans to acquire CartiHeal for $500 million

Bioventus has made a $50 million escrow payment signaling its intent to acquire Israeli medtech company CartiHeal for approximately $500 million, pending FDA approval of CartiHeal's Agili-C implant.

- Type: Acquisition
- Announced: 2021-08-30
- Where: Israel
- Value: $500.0M
- Status: announced
- Products: Agili-C implant for cartilage repair
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bioventus Inc.](https://endata.com/companies/54140.md) (acquirer)
- [CartiHeal](https://endata.com/companies/57427.md) (target)

## Sources

- [beckersspine.com](https://www.beckersspine.com/biologics/bioventus-lines-up-another-500m-acquisition-5-details/), 2021-08-31: "We believe this product could be a strong alternative for the approximately 650,000 U.S. patients annually receiving microfracture or debridement along with other cartilage treatment options."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.